Publicações

525Mo Updated Efficacy and Safety of Lenvatinib (Len) + Pembrolizumab (Pembro) Vs Treatment of Physician’s Choice (Tpc) in Patients (Pts) with Advanced Endometrial Cancer (Aec): Study 309/Keynote-775

AuthID
P-00Y-B6B

Author(s)

Makker, V

Colombo, N

Casado Herraez, A

Monk, B

Mackay, H

Santin, A

Miller, D

Moore, R

Baron-Hay, S

Ray-Coquard, I

Shapira-Frommer, R

Ushijima, K

Yonemori, K

Kim, Y

Guerra Alia, E

Sanli, U

Huang, J

McKenzie, J

Barresi, G

Lorusso, D

Tipo de Documento

Article

Year published

2022

Publicado

in Annals of Oncology, ISSN: 0923-7534

Volume: 33, Páginas: S785-S786

Indexing

Crossref^®1

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1016/j.annonc.2022.07.653

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

525Mo Updated Efficacy and Safety of Lenvatinib (Len) + Pembrolizumab (Pembro) Vs Treatment of Physician’s Choice (Tpc) in Patients (Pts) with Advanced Endometrial Cancer (Aec): Study 309/Keynote-775

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

525Mo Updated Efficacy and Safety of Lenvatinib (Len) + Pembrolizumab (Pembro) Vs Treatment of Physician’s Choice (Tpc) in Patients (Pts) with Advanced Endometrial Cancer (Aec): Study 309/Keynote-775

Links Úteis

Ajuda